UBS initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy. PT $64.00.

The firm comments, "Our investment thesis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE